Sandoz launches intravenous medicine generic Ferumoxytol for iron deficiency anemia

Ferumoxytol, a generic equivalent to AMAG Pharmaceuticals' Feraheme (ferumoxytol injection), is approved to treat IDA in adult patients who have an intolerance to oral iron or have had an unsatisfactory response to oral iron, or who have chronic kidney disease. The overall global IV iron market is over a one billion dollar market and continues to grow.

"As the first generic high dose IV iron available in the US, Ferumoxytol provides patients with iron deficiency anemia a more cost-effective treatment option," said Keren Haruvi, President, Sandoz Inc. "This launch delivers on our strategy to continue to build our hospital and clinic portfolio and provide US patients access to affordable generic medicines that work as well as brand-name products."

Read also: ANI Pharma acquires Sandoz NDAs to expand branded products portfolio

Sandoz initially plans to make its generic Ferumoxytol medicine available to patients in the hospital and clinic setting. Intravenous administration of iron has been shown to be more effective, more rapidly, than a prolonged course of oral iron therapy in patients with IDA.

Read also: Sandoz launches biosimilar Hyrimoz in Canada